Trials / Unknown
UnknownNCT02101957
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- University Hospital, Angers · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study group 1996).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RP103 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2015-07-01
- First posted
- 2014-04-02
- Last updated
- 2014-04-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02101957. Inclusion in this directory is not an endorsement.